What is Lu PSMA (Lutetium-Prostate Specific Membrane Antigen) Therapy?

Lu177 PSMA Therapy is a treatment for patients with prostate cancer, especially those who have become refractory to conventional therapy. Lutetium PSMA therapy helps to slow down the growth of the cancer cells, reduce the size of the tumours and most importantly improve the quality of life of the patients by reducing the pain caused by the cancer.

Many prostate cancers, in particular those that have spread or become resistant to hormonal therapies, express a unique receptor on their cell surface called Prostate Specific Membrane Antigen (PSMA). When Prostate Cancer metastasizes i.e. spreads to other parts of the body, the PSMA receptor is expressed over the sites of metastases as well.

How does Lu PSMA Therapy Work?

Lutetium-177 is a radioactive substance that emits beta radiation, a destructive kind of radiation. Lutetium-177 is bound to a small peptide which attaches to the PSMA receptor expressed on the cancer cell surface. The Lutetium 177 – PSMA complex, thus attached to the prostate cancer cell, then emits killing radiation causing cell death of the cancer cell. Since the penetration of the emitted beta particle is very small, the surrounding normal cells are spared.

How is the Therapy Done?

Lu177 PSMA is administered intravenously. The patient is admitted to the hospital for 24 hours. A kidney function scan called a MAG3/EC scan is done prior to the administration of the Lu177 PSMA.

What are the Side Effects of Lu PSMA Therapy?

Lu177 PSMA is well tolerated. The most common side effects are a slightly dry mouth, fatigue and nausea. There may also be a slight fall in the white blood cells and platelets about 2 – 3 weeks after the Lu177 PSMA administration.

What is the Response Rate With Lu PSMA Therapy?

The response rates of Lu177 PSMA depend on the tumour biology of prostate cancer, the initial Gleason Score, the extent of disease and the responses to prior therapies. Typically, more than 70% of patients demonstrate a reduction in S. PSA and a shrinkage of tumours following Lu177 PSMA therapy.

When would the doctor consider using this Therapy?

Lu PSMA Therapy is a very specific therapy and is used for managing metastatic Prostate Cancer or when Prostate Cancer is no longer responsive to other types of treatment.

What are the Treatment Schedules with Lu PSMA Therapy?

Most patients undergo three-four treatment cycles at intervals of 8-12 weeks. The number of cycles and the interim duration may vary between individuals depending on the response and interim assessments.

Why should I choose the nuclear medicine therapy center at Fortis Memorial & Research Institute (FMRI), Gurugram (Haryana, India)?

The Nuclear Medicine Therapy Centre at FMRI was one of the first institutes to offer Radio-ligand Therapy with Lu PSMA, and today, the center receives patients from the country and from across the world.

Dr. Parul Thakral - Ph.D, M.Sc., Clinical Research Officer

With a Ph.D in Radiochemistry & Clinical Nuclear Medicine from one of Asia’s Premier Institutes, AIIMS (All India Institute of Medical Sciences), Dr. Parul Thakral is currently working as a Clinical Research Officer in the Department of Nuclear Medicine & Molecular Imaging at Fortis Memorial Research Institute (FMRI), Gurgaon.

Dr. Parul’s interest in Clinical Research began during her school days. After completing her graduation, B.Sc – Medical Technology in Radiography, and post-graduation, M.Sc. – Nuclear Medicine Technology from AIIMS, she started working as a Senior Research Fellow on a DST Funded Projects at the Department of Nuclear Medicine at AIIMS.

Dr. Parul’s Ph.D Thesis’ topic was “ASSESMENT OF THERAPEUTIC RESPONSE TO 90YTTRIUM (90Y) RADIOLABELLED CHIMERIC ANTI-CD20 ANTIBODY - RITUXIMAB IN PATIENTS OF RELAPSED/ REFRACTORY B-CELL NON-HODGKIN’S LYMPHOMA,” where she was involved conjugation & standardisation of Radiolabelling and quality control of Ant-CD20 Monoclonal Antibody Rituximab with 90-Yttrium, 68-Gallium & 177-Lutetium.

With Radiolabelling of Monoclonal Antibodies (Human & Non-Human) as her forte, Dr. Parul has extensive experience working with several Radionuclides & Radiopharmaceuticals, such as Tc-99m (TRODAT, Methionine) I-131, F-18(NaF, FDOPA, FLT), Ga-68 (DOTANOC, PSMA, Bisphosphonate), Lu-177 (Rituximab, DOTATATE, PSMA), Y-90 (Rituximab), Sr-89, Sm-155, P-32, Re-186 & Re-188. Apart from this, she also has expertise in Chromatographic Procedures (TLC & HPLC).

Dr. Parul is also an AERB Radiation Safety Officer (RSO), Level-II and a visiting faculty for M.Sc (Nuclear Medicine) at Ganesh Educational & Research Institute in New Delhi.

Dr. Parul Thakral

Experience

Achievement

Consult Dr Ishita B Sen